Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	9 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Operating activities
Net loss	$ (8,880,961)	$ (5,040,998)
Adjustments to reconcile net loss to net cash and cash equivalents used in operating activities:
Depreciation and amortization	2,447,359	1,180,206
Rent expense from operating lease right-of-use asset	354,810
Bad debt expense	207,010	69,613
Reserve for contract asset	960,000
Stock-based compensation	1,231,939	1,889,175
Release of valuation allowance on deferred tax assets	(4,540,000)
Changes in operating assets and liabilities:
Accounts receivable	(3,317,969)	(157,903)
Inventories	(9,000,757)	(2,004,812)
Prepaid expenses and other current assets	(852,408)	(252,805)
Lease and other assets	617,028	83,453
Accounts payable, accrued expenses and other current liabilities	(537,552)	1,632,102
Net cash used in operating activities	(21,311,501)	(2,601,969)
Investing activities
Acquisition of property, plant and equipment	(304,855)	(588,526)
Additional patents	(104,694)	(127,912)
Cash from acquisition of Solsys Medical, LLC	5,525,601
Net cash provided by (used in) investing activities	5,116,052	(716,438)
Financing activities
Proceeds from notes payable	28,750,000
Repayments of notes payable	(12,569,940)
Stock registration and investment bank fees	(3,859,036)
Proceeds from equity offering	34,572,062
Proceeds from exercise of stock options	1,185,416	1,351,172
Net cash provided by financing activities	48,078,502	1,351,172
Net increase (decrease) in cash and cash equivalents	31,883,053	(1,967,235)
Cash and cash equivalents at beginning of year	7,842,403	10,979,455
Cash and cash equivalents at end of year	39,725,456	9,012,220
Cash paid for:
Interest	1,397,191
Income taxes	550	71,787
Transfer of inventory to property, plant and equipment for consignment of product	3,536,488	692,112
Stock issued for the acquisition of Solsys Medical, LLC	$ 108,643,710